Skip to main content
. Author manuscript; available in PMC: 2014 Apr 29.
Published in final edited form as: J Intern Med. 2010 Feb;267(2):139–155. doi: 10.1111/j.1365-2796.2009.02202.x

Figure 1.

Figure 1

Potential pharmacogenetic considerations in optimizing stroke prevention. Genetic testing could be used to stratify risk of future large vessel atherosclerotic stroke or cardioembolic stroke. Genetic testing could also be used to help safely initiate warfarin anticoagulation or identify individuals not likely to respond to clopidogrel. It could also be used to identify individuals at risk of myositis associated with statin use.